Talk:TOPCAT

Criticisms

I'm sure it's sensible, but I can't make sense of this statement:

Use of HF hospitalization in prior year as inclusion criteria may have enrolled individuals less likely to benefit from spironolactone as there is at least some evidence that individuals with elevated BNP have LV remodeling and would be more likely to benefit from aldosterone antagonism

Why would this be? We should address it here. --Dave Iberri (talk) 14:10, 15 July 2014 (UTC)

I just read the letters to the editor. That statement about using HF hospitalization in the prior year to identity pts with HFpEF is really just to say that the diagnosis is hard to nail down and therefore recent HF hospitalization may not adequately select pts with true HFpEF. The BNP statement is really one about identifying pts with ventricular remodeling, and is a separate issue from the HF hospitalization one. I've removed the statement entirely, but cited the letters I the editor in the criticism of the definition of HFpEF. See my edit from just a few mins ago. --Dave Iberri (talk) 14:20, 15 July 2014 (UTC)